Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels?: reply from …
M de Bruin-Weller, NMH Graham, G Pirozzi… - The British journal of …, 2018 - europepmc.org
This is a comment on" Dupilumab with concomitant topical corticosteroid treatment in adults
with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when
this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical
trial (LIBERTY AD CAFÉ)." Br J Dermatol. 2018 May; 178 (5): 1083-1101. This is a comment
on" Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused
by colonization with Demodex and increased interleukin-17 levels?" Br J Dermatol. 2018 …
with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when
this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical
trial (LIBERTY AD CAFÉ)." Br J Dermatol. 2018 May; 178 (5): 1083-1101. This is a comment
on" Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused
by colonization with Demodex and increased interleukin-17 levels?" Br J Dermatol. 2018 …
Conjunctivitis in patients with atopic dermatitis treated with dupilumab
S Ferreira, T Torres - Drugs in Context, 2020 - pmc.ncbi.nlm.nih.gov
Atopic dermatitis (AD) is a common, chronic, inflammatory skin disorder with high physical
and emotional burden. Robust evidence suggests that interleukin (IL)-4 and IL-13 are key
cytokines in the immunopathogenesis of AD. New emerging agents include dupilumab, a
fully human monoclonal antibody directed against the IL-4 receptor a subunit that blocks
both IL-4 and IL-13 signaling and has shown significant efficacy in patients with moderate-to-
severe AD. Dupilumab is approved for the treatment of moderate-to-severe AD, moderate-to …
and emotional burden. Robust evidence suggests that interleukin (IL)-4 and IL-13 are key
cytokines in the immunopathogenesis of AD. New emerging agents include dupilumab, a
fully human monoclonal antibody directed against the IL-4 receptor a subunit that blocks
both IL-4 and IL-13 signaling and has shown significant efficacy in patients with moderate-to-
severe AD. Dupilumab is approved for the treatment of moderate-to-severe AD, moderate-to …
